Vanguard Group
LAB icon

Vanguard Group’s Standard BioTools LAB Stock Holding History

Vanguard Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$22.1M Buy
17,297,599
+52,016
+0.3% +$69.9K ﹤0.01% 2575
2025
Q3 		$22.4M Buy
17,245,583
+263,845
+2% +$346K ﹤0.01% 2563
2025
Q2 		$20.4M Sell
16,981,738
-243,512
-1% -$270K ﹤0.01% 2549
2025
Q1 		$18.6M Buy
17,225,250
+69,104
+0.4% +$97K ﹤0.01% 2535
2024
Q4 		$30M Sell
17,156,146
-135,946
-0.8% -$253K ﹤0.01% 2393
2024
Q3 		$33.4M Buy
17,292,092
+1,288,934
+8% +$2.52M ﹤0.01% 2358
2024
Q2 		$28.3M Buy
16,003,158
+2,969,115
+23% +$7.26M ﹤0.01% 2389
2024
Q1 		$35.3M Buy
13,034,043
+8,900,104
+215% +$21.5M ﹤0.01% 2321
2023
Q4 		$9.14M Buy
4,133,939
+159,413
+4% +$340K ﹤0.01% 2998
2023
Q3 		$11.5M Buy
3,974,526
+31,636
+0.8% +$82.7K ﹤0.01% 2807
2023
Q2 		$7.61M Sell
3,942,890
-13,078
-0.3% -$25.8K ﹤0.01% 3104
2023
Q1 		$7.71M Hold
3,955,968
– – ﹤0.01% 3083
2022
Q4 		$4.63M Buy
3,955,968
+1,614
+0% +$1.99K ﹤0.01% 3341
2022
Q3 		$4.35M Buy
3,954,354
+396,800
+11% +$600K ﹤0.01% 3398
2022
Q2 		$5.69M Sell
3,557,554
-359,278
-9% -$889K ﹤0.01% 3308
2022
Q1 		$14.1M Buy
3,916,832
+49,161
+1% +$170K ﹤0.01% 2968
2021
Q4 		$15.2M Buy
3,867,671
+280,792
+8% +$1.31M ﹤0.01% 2982
2021
Q3 		$23.6M Sell
3,586,879
-76,966
-2% -$506K ﹤0.01% 2769
2021
Q2 		$22.6M Sell
3,663,845
-71,225
-2% -$381K ﹤0.01% 2775
2021
Q1 		$16.9M Buy
3,735,070
+258,760
+7% +$1.42M ﹤0.01% 2870
2020
Q4 		$20.9M Sell
3,476,310
-52,965
-2% -$348K ﹤0.01% 2612
2020
Q3 		$26.2M Sell
3,529,275
-402,307
-10% -$2.78M ﹤0.01% 2324
2020
Q2 		$15.8M Sell
3,931,582
-528,106
-12% -$1.84M ﹤0.01% 2541
2020
Q1 		$11.3M Buy
4,459,688
+49,912
+1% +$164K ﹤0.01% 2562
2019
Q4 		$15.3M Buy
4,409,776
+6,466
+0.1% +$22.7K ﹤0.01% 2653
2019
Q3 		$20.4M Buy
4,403,310
+656,502
+18% +$5.17M ﹤0.01% 2487
2019
Q2 		$46.2M Buy
3,746,808
+1,711,187
+84% +$21.8M ﹤0.01% 2143
2019
Q1 		$27.1M Buy
2,035,621
+240,425
+13% +$2.53M ﹤0.01% 2370
2018
Q4 		$15.5M Buy
1,795,196
+384,670
+27% +$3M ﹤0.01% 2560
2018
Q3 		$10.6M Buy
1,410,526
+121,815
+9% +$866K ﹤0.01% 2889
2018
Q2 		$7.68M Sell
1,288,711
-48,623
-4% -$277K ﹤0.01% 3032
2018
Q1 		$7.81M Buy
1,337,334
+12,545
+0.9% +$82.4K ﹤0.01% 2949
2017
Q4 		$7.8M Buy
1,324,789
+138,716
+12% +$759K ﹤0.01% 2943
2017
Q3 		$5.98M Buy
1,186,073
+534,196
+82% +$2.25M ﹤0.01% 3045
2017
Q2 		$2.63M Sell
651,877
-530,006
-45% -$2.51M ﹤0.01% 3298
2017
Q1 		$6.72M Buy
1,181,883
+19,669
+2% +$125K ﹤0.01% 2940
2016
Q4 		$8.46M Buy
1,162,214
+29,771
+3% +$187K ﹤0.01% 2825
2016
Q3 		$9.07M Buy
1,132,443
+49,259
+5% +$452K ﹤0.01% 2736
2016
Q2 		$9.78M Buy
1,083,184
+24,638
+2% +$232K ﹤0.01% 2660
2016
Q1 		$8.54M Buy
1,058,546
+74,139
+8% +$535K ﹤0.01% 2696
2015
Q4 		$10.6M Sell
984,407
-13,454
-1% -$132K ﹤0.01% 2600
2015
Q3 		$8.09M Buy
997,861
+20,931
+2% +$329K ﹤0.01% 2715
2015
Q2 		$23.6M Buy
976,930
+29,381
+3% +$927K ﹤0.01% 2279
2015
Q1 		$39.9M Buy
947,549
+55,790
+6% +$2.21M ﹤0.01% 2021
2014
Q4 		$30.1M Buy
891,759
+37,284
+4% +$1.06M ﹤0.01% 2077
2014
Q3 		$20.9M Buy
854,475
+6,612
+0.8% +$186K ﹤0.01% 2184
2014
Q2 		$24.9M Buy
847,863
+46,105
+6% +$1.48M ﹤0.01% 2135
2014
Q1 		$35.3M Buy
801,758
+122,592
+18% +$5.39M ﹤0.01% 1983
2013
Q4 		$26M Buy
679,166
+106,191
+19% +$3.13M ﹤0.01% 2073
2013
Q3 		$12.6M Buy
572,975
+47,306
+9% +$929K ﹤0.01% 2288
2013
Q2 		$9.18M Buy
+525,669
New +$9.22M ﹤0.01% 2363

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group's LAB Position: Q4 2025 in Review

Vanguard Group increased its Standard BioTools (LAB) stake by 0.3% in Q4 2025, buying an estimated $69.9K and bringing the position to 17,297,599 shares worth $22.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2575.

Vanguard Group first reported a position in LAB in Q2 2013 and has held it in 51 quarters since. The position peaked at $46.2M in Q2 2019. 159 funds tracked by Wall St. Rank hold LAB as of Q4 2025.

  • Vanguard Group held 17,297,599 shares of Standard BioTools worth $22.1M as of Q4 2025.
  • Vanguard Group bought 52,016 Standard BioTools shares in Q4 2025, an estimated $69.9K.
  • Standard BioTools made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2575 holding.
  • Vanguard Group first reported a position in Standard BioTools in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Standard BioTools position peaked at $46.2M in Q2 2019.
  • 159 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.